Voglibose Tablets 0.2 mg, 0.3 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 0.2 mg, 0.3 mg

Reference Brands: Basen® (Asia)

Category: Diabetes

Voglibose 0.2 mg and 0.3 mg tablets, an alpha-glucosidase inhibitor taken before meals in type 2 diabetes. For importers, distributors and diabetes tender buyers in markets where voglibose is registered.

Product Description:

Voglibose is an alpha-glucosidase inhibitor, a valiolamine derivative that works inside the small intestine. It blocks the brush-border enzymes that split disaccharides into glucose, so carbohydrate is absorbed more slowly and the rise in blood glucose after a meal is flattened. This page covers tablets of 0.2 mg and 0.3 mg. The doses are tiny, so content uniformity matters, and orally disintegrating versions exist in some markets.

It is used in type 2 diabetes to control blood glucose after meals, alone with diet and exercise or added to metformin, sulfonylureas or insulin. The tablet is taken immediately before each main meal, usually three times a day. Flatulence, bloating and diarrhoea are common at the start. On its own it rarely causes hypoglycaemia, but it can with a sulfonylurea or insulin; glucose, not table sugar, must then be used, because sucrose breakdown is blocked. Labels advise caution after abdominal surgery, with a history of bowel obstruction and in significant liver disease.

Sourcing notes. Voglibose is registered in Japan, India and other Asian markets but not in the US or most of the EU, so confirm approval in your destination first. Fixed-dose combinations with metformin, and sometimes glimepiride, are common in some markets; check that the combination is approved in your market. The CTD or ACTD dossier should show content uniformity and an assay sensitive enough for such a low dose, plus zone IVb stability. Tablets ship at room temperature in moisture-protective blisters. Documents to collect are a CoA per lot, a GMP certificate and a CoPP.